Korean Circulation Journal

  • 제54권10호
  • /
  • Pages.619-633
  • /
  • 2024
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

Long-term Outcome of Cryoballoon Ablation in Korean Patients With Atrial Fibrillation: Real-World Experience From the Cryo Global Registry

  • Houngbeom Ahn (Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Seoul National University Bundang Hospital) ;
  • Hong Euy Lim (Division of Cardiology, Department of Internal Medicine, Hallym University Sacred Heart Hospital) ;
  • Young Keun On (Division of Cardiology, Department of Medicine, Cardiac Arrhythmia Center, Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Jada M Selma (Cardiac Ablation Solutions, Medtronic, Inc.) ;
  • Fred J Kueffer (Cardiac Ablation Solutions, Medtronic, Inc.) ;
  • Kelly Anna van Bragt (Cardiac Ablation Solutions, Medtronic, Inc.) ;
  • Valentine Obidigbo (Cardiac Ablation Solutions, Medtronic, Inc.) ;
  • Il-Young Oh (Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Seoul National University Bundang Hospital)
  • 투고 : 2024.01.29
  • 심사 : 2024.05.07
  • 발행 : 2024.10.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background and Objectives: Atrial fibrillation (AF), the most common atrial arrhythmia (AA), is an increasing healthcare burden in Korea. The objective of this sub-analysis of the Cryo Global Registry was to evaluate long-term efficacy, symptom burden, quality of life (QoL), and healthcare utilization outcomes and factors associated with AA recurrence in Korean patients treated with cryoballoon ablation (CBA). Methods: Patients were treated and followed up according to local standard-of-care in 3 Korean hospitals. Kaplan-Meier estimates were used in analyzing (1) efficacy defined as freedom from ≥30 second recurrence of AA at 24 months, (2) healthcare utilization, and (3) predictors of 24-month AA recurrence. Patient-reported QoL (using European Quality of Life-5 Dimensions-3 Levels) and predefined AF-related symptoms were assessed at baseline and 24-month follow-up. Results: Efficacy was 71.9% in paroxysmal AF (PAF) and 49.3% in persistent AF (PsAF) patients (p<0.01). A larger left atrial diameter (LAD), an increased time from AF diagnosis to CBA, and PsAF were independent predictors of AA recurrence. The percentage of patients with no AF symptoms significantly increased from baseline (24.5%) to 24-month (89.5%) follow-up (p<0.01). Improvement in QoL from baseline to 24 months was not statistically different between AF cohorts. PAF patients experienced greater freedom from repeat ablations (93.9% vs. 81.4%) and cardiovascular hospitalizations (91.3% vs. 72.5%, p<0.001 for both). Conclusions: In alignment with global outcomes, CBA is an effective treatment for AF in the Korean population, with patients possessing a large LAD and not receiving ablation soon after diagnosis being the most at risk for AA recurrence.

키워드

과제정보

The authors sincerely thank the Cryo Global Registry Korea site staff for their commitment and contributions to the study. The authors also thank Jihyun Jung, Hae Lim, and Ryan Radtke from Medtronic for their support of the trial and generation of this manuscript.

참고문헌

  1. Lee SR, Choi EK, Han KD, Cha MJ, Oh S. Trends in the incidence and prevalence of atrial fibrillation and estimated thromboembolic risk using the CHA2DS2-VASc score in the entire Korean population. Int J Cardiol 2017;236:226-31. https://doi.org/10.1016/j.ijcard.2017.02.039
  2. Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med 2021;384:305-15. https://doi.org/10.1056/NEJMoa2029980
  3. Kuck KH, Furnkranz A, Chun KR, et al. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. Eur Heart J 2016;37:2858-65. https://doi.org/10.1093/eurheartj/ehw285
  4. Ganesan AN, Shipp NJ, Brooks AG, et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc 2013;2:e004549.
  5. Lim HE, Oh IY, Kueffer FJ, van Bragt KA, On YK. Cryoballoon catheter ablation in Korean patients with paroxysmal and persistent atrial fibrillation: one year outcome from the Cryo Global Registry. Korean Circ J 2022;52:755-67. https://doi.org/10.4070/kcj.2022.0127
  6. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation 2024;149:e1-156.
  7. Song W, Lv T, Zhang N, Li G, Tse G, Liu T. Long-term efficacy and safety of cryoballoon ablation of atrial fibrillation: a systematic review and meta-analysis. Pacing Clin Electrophysiol 2024;47:49-57. https://doi.org/10.1111/pace.14881
  8. Chun KR, Okumura K, Scazzuso F, et al. Safety and efficacy of cryoballoon ablation for the treatment of paroxysmal and persistent AF in a real-world global setting: results from the Cryo AF Global Registry. J Arrhythm 2021;37:356-67. https://doi.org/10.1002/joa3.12504
  9. Goya M, Frame D, Gache L, et al. The use of intracardiac echocardiography catheters in endocardial ablation of cardiac arrhythmia: meta-analysis of efficiency, effectiveness, and safety outcomes. J Cardiovasc Electrophysiol 2020;31:664-73. https://doi.org/10.1111/jce.14367
  10. Kuwahara T. Intracardiac echocardiography in catheter ablation for atrial fibrillation: it is better to see what you are doing? J Atr Fibrillation 2015;7:1215.
  11. Dello Russo A, Russo E, Fassini G, et al. Role of intracardiac echocardiography in atrial fibrillation ablation. J Atr Fibrillation 2013;5:786.
  12. Kimura M, Kobori A, Nitta J, et al. Cryoballoon ablation for paroxysmal atrial fibrillation in Japan: 2-year safety and efficacy results from the Cryo AF Global Registry. J Interv Card Electrophysiol 2022;64:695-703. https://doi.org/10.1007/s10840-022-01132-0
  13. Choi JH, Park SJ, Park KM, Kim JS, On YK. Efficacy and safety of cryoballoon pulmonary vein isolation for paroxysmal and persistent atrial fibrillation: a comparison with radiofrequency ablation. PLoS One 2022;17:e0265482.
  14. Wu SJ, Li CH, Weng CJ, et al. Efficacy of cryoballoon ablation for atrial fibrillation and recurrence predictors in an asian cohort. J Pers Med 2022;12:732.
  15. Pak HN, Park JW, Yang SY, et al. Cryoballoon versus high-power, short-duration radiofrequency ablation for pulmonary vein isolation in patients with paroxysmal atrial fibrillation: a single-center, prospective, randomized study. Circ Arrhythm Electrophysiol 2021;14:e010040.
  16. Scazzuso F, Ptaszynski P, Kaczmarek K, et al. Regional variations in patient selection and procedural characteristics for cryoballoon ablation of atrial fibrillation in the Cryo Global Registry. J Interv Card Electrophysiol 2023;67:493-501. https://doi.org/10.1007/s10840-023-01582-0
  17. Bavishi AA, Kaplan RM, Peigh G, et al. Patient characteristics as predictors of recurrence of atrial fibrillation following cryoballoon ablation. Pacing Clin Electrophysiol 2019;42:694-704. https://doi.org/10.1111/pace.13669
  18. Quan D, Huang H, Kong B, Li Q, Liao J, Wang G. Predictors of late atrial fibrillation recurrence after cryoballoon-based pulmonary vein isolation: a meta-analysis. Kardiol Pol 2017;75:376-85. https://doi.org/10.5603/KP.a2016.0186
  19. Lawin D, Stellbrink C, Chun K, et al. Efficacy and safety outcomes of early versus late cryoballoon ablation of atrial fibrillation-24-months-results from the Cryo Global Registry. EP Europace 2023;25:euad122.682.
  20. Chew DS, Black-Maier E, Loring Z, et al. Diagnosis-to-ablation time and recurrence of atrial fibrillation following catheter ablation: a systematic review and meta-analysis of observational studies. Circ Arrhythm Electrophysiol 2020;13:e008128.
  21. Ciconte G, Ottaviano L, de Asmundis C, et al. Pulmonary vein isolation as index procedure for persistent atrial fibrillation: one-year clinical outcome after ablation using the second-generation cryoballoon. Heart Rhythm 2015;12:60-6. https://doi.org/10.1016/j.hrthm.2014.09.063
  22. Neumann T, Wojcik M, Berkowitsch A, et al. Cryoballoon ablation of paroxysmal atrial fibrillation: 5-year outcome after single procedure and predictors of success. Europace 2013;15:1143-9.
  23. Marrouche NF, Wilber D, Hindricks G, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA 2014;311:498-506. https://doi.org/10.1001/jama.2014.3
  24. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002;54:230-46. https://doi.org/10.1016/S0008-6363(02)00258-4
  25. Helms AS, West JJ, Patel A, et al. Relation of left atrial volume from three-dimensional computed tomography to atrial fibrillation recurrence following ablation. Am J Cardiol 2009;103:989-93. https://doi.org/10.1016/j.amjcard.2008.12.021
  26. Su WW, Reddy VY, Bhasin K, et al. Cryoballoon ablation of pulmonary veins for persistent atrial fibrillation: results from the multicenter STOP Persistent AF trial. Heart Rhythm 2020;17:1841-7. https://doi.org/10.1016/j.hrthm.2020.06.020
  27. Chierchia GB, Pavlovic N, Velagic V, et al. Quality of life measured in first-line therapy during the Cryo-FIRST study: a comparison between cryoballoon catheter ablation versus antiarrhythmic drug therapy. Eur Heart J 2020;41:ehaa946.0436. 
  28. Andrade JG, Champagne J, Deyell MW, et al. A randomized clinical trial of early invasive intervention for atrial fibrillation (EARLY-AF) - methods and rationale. Am Heart J 2018;206:94-104. https://doi.org/10.1016/j.ahj.2018.05.020
  29. Khelae SK, Kyoung-Ryul Chun J, Drephal C, et al. PO-679-05 differences in atrial fibrillation cryoballoon ablation by gender: 24-month outcomes from the Cryo AF Global Registry. Heart Rhythm 2022;19:S354-5.